Belmont, CA – According to filings with the U.S. Securities and Exchange Commission, VelosBio is raising $59,305,204.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Johnson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About VelosBio

VelosBio Inc. is a next-generation oncology company, developing novel antibody-drug conjugates (ADCs) to treat haematological cancers and solid tumours. VelosBio has a highly experienced leadership team, led by Chief Executive Officer, Dave Johnson, the former CEO of Acerta Pharma. VelosBio’s Executive Vice President of Development and Chief Medical Officer, Langdon Miller, MD, is an accomplished drug development expert with over 25 years of experience in the design and conduct of translational and clinical drug development programmes in oncology and orphan diseases.

To learn more about VelosBio, visit http://velosbio.com/

Contact:
David Johnson, Chief Executive Officer
858-357-4137
djohnson@velosbio.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved